Verona Pharma PLC (VRNA) FinancialsVRNAVerona Pharma PLC

Evaluating the bottom line, Verona Pharma PLC maintains a gross margin of 95.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.90%, while the net margin is 11.56%. These profitability ratios, combined with a Return on Equity (ROE) of -37.37%, provide a clear picture of how effectively VRNA converts its operational activities into shareholder value.

In the context of the broader market, VRNA competes directly with industry leaders such as CORT and MDGL. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, VRNA's gross margin of 95.39% stands against CORT's 98.41% and MDGL's 89.02%. Such benchmarking helps identify whether Verona Pharma PLC is trading at a premium or discount relative to its financial performance.